No abstract

No abstract

Background Recently there have been studies showing the presence of inflammatory joint activity in patients with systemic lupus erythematosous (SLE) without musculoskeletal symptoms. The predictive value of these findings remains unknown. On the other hand, there is a proportion of healthy patients where synovitis can be demonstrated as a result of recent mechanical overexertion. Objectives The aim of this study is to compare the sonographic findings of SLE patients without joint symptoms with healthy people. Methods An ultrasonographic study (USS) was performed, using a linear probe for soft tissues (5-12 MHz), to 15 patients newly diagnosed with SLE and 44 healthy subjects matched for age and sex. The areas studied were: back of the wrist, 2nd and 3rd metacarpophalangeal joint (MCP) and 2nd and 3rd flexor tendon. The studies were performed in the nondominant hand. We determined the presence of synovitis, tenosynovitis and tendinosis and measured the thickness of the flexor tendons. Dichotomous variables were analyzed using the chi-square test and numerical variables through the Student t test. Results Controls were matched with SLE patients of the same sex and age with a maximum difference of ± 3 years. SLE patients came from a cohort previously used in another study with no less than 5 years follow-up. Controls were healthy volunteer patients from the osteoporosis clinics or patients with localized non-inflammatory diseases outside the field of USS. Carpal sinovitis was seen in 33,3% of SLE patients and 27,2% of controls (p<0,05); metacarpophalangeal (MCP) synovitis was seen in 33,3% of SLE patients and 13,6% of controls (p<0,05); carpal tenosynovitis was seen in 40% of SLE patients and 13,6% of controls (p<0,05). The height of the synovial capsule of the carpal joint was 3,67±0,21 in SLE patients and 2,99±0,30 in the control group (p<0,001); Thickness of the extensor sheath was 2,99±0,42 in SLE patients and 2,49±0,36 in the control group (p<0,05); height of the capsule of the 2nd MCP joint was 3,19±0,27 in SLE patients and 3,04±0,19 in the control group (p>0,05); height of the capsule of the 3rd MCP joint was 2,91±0,52 in SLE patients and 2,54±0,32 in the control group. In order to compare MCP capsules height we assay a corection using the lenght of the major axis of the joint. The fixed height of the 2nd MCP was 0,461±0,121 and 0,406±0,098 (SLE/controls) (p<0,001); the fixed height of the 3rd MCP was 0,445±0,200 and 0,3642±0,117 (p<0,001). Conclusions Our results suggest that the population of SLE patients without joint symptoms present sonographic findings suggestive of joint inflammation and tendon involvement that can not be explained by the acceptable changes that can be found in disease-free population, however, interpretation of their evolutionary significance has not been clarified. The role of time since diagnosis in the development of synovitis or tendinosis, or corticoids in the development of tendinosis may be revealed with studies with larger amounts of patients. Disclosure of Interest None D...

BackgroundSystemic Lupus Erythematosus (SLE) is an autoimmune systemic rheumatic disease that, in our area, presents hematologic manifestations in approximately 70% of cases1. Some of them are very rare so there are no large series whose analysis could provide relevant information.ObjectivesTo study the characteristics of patients with Hemophagocytic Syndrome (HS) in a large sample of SLE patients.MethodsSLE patients from RELESSER database were studied. We analysed SLE manifestations present at 12 different domains (mucocutaneous, renal, musculoskeletal, constitutional, hematologic, vascular, cardiac, respiratory, neuropsychiatric, gastrointestinal, ophthalmic and serological) before, during and after HS diagnosis and until the last available assessment. We also studied activity (SELENA-SLEDAI) and damage (SLICC/ACR DI) indices at those moments.We evaluated the treatment received, HS recurrences and the number of deaths by this entity.Results3,656 SLE patients (≥4 ACR criteria) from 45 Rheumatology Units across Spain were studied. Seven patients (<0.5%) with HS were identified. 71.4% were women, with a mean age (± S.D.) at SH diagnosis of 35.1 (± 17.1) years. In 5 of the 7 cases the HS occurred 115.5 (± 162.9) months after SLE diagnosis. In the other 2 cases the diagnosis of both entities was simultaneous. The main triggers of HS were infections, followed by SLE activity flares. At the time of HS diagnosis, they had high SLE activity with a mean SLEDAI score of 13.1 (± 11.3) and 1.4 (± 2.3) SDI score.Clinically, 100% of the patients presented fever and alterations of the liver profile, 85.8% cytopenias and 71.5% dermatological manifestations. Respiratory manifestations and hemolytic anemia were present in 57.2% of the cases, both; lymph nodes and coagulopathy in 42.9%. Hepatomegaly was detected in 28.6%, as well as neuropsychiatric, digestive and renal manifestations. Splenomegaly was detected in 14.3%. The mean hemoglobin level was 8.6 (± 1.1) g/dl, platelets 85,585 (± 83,390)/mm3, ferritin 7,410 (± 6,470) ng/ml and triglycerides 404.7 (± 235.6) mg/dl. All patients were admitted and undergonebone marrow study, requiring a mean of 2.2 (± 1.5) treatment lines, using 2.8 (± 1.7) drugs. One patient died during the HS episode by the HS itself and another 2 patients had 2 and 3 recurrences, respectively.The following table shows the characteristics of each patient.ConclusionsHS is a rare life-threatening SLE manifestation. It must be suspected in SLE patients with persistent fever who do not respond to antibiotics, cytopenias and evidence of multiorgan involvement. Relapses and death are common in HS associated to SLE.References Pego-Reigosa JM, Rua-Figueroa I, Lopez-Longo FJ, Galindo-Izquierdo M, Calvo-Alen J, Olive-Marques A, et al. Analysis of disease activity and response to treatment in a large Spanish cohort of s with systemic lupus erythematosus. Lupus 2015;24:720–9. AcknowledgementsWork supported by Spanish Society of Rheumatology, FIS/ISCIII (PI11/02857), BIOCAPS from the European Union 7th Framework Programme...